INO80B-WBP1: A Promising Drug Target / Biomarker (G100532735)

Target Name: INO80B-WBP1

NCBI ID: G100532735

INO80B-WBP1

Other Name(s): INO80B-WBP1 readthrough (NMD candidate)

INO80B-WBP1: A Promising Drug Target / Biomarker

INO80B-WBP1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns have made it an attractive target for researchers to study and potentially exploit its functions in the human body.

Structure and Expression

INO80B-WBP1 is a small non-coding RNA molecule that contains 21 amino acid residues and 80 non-coding nucleotide residues. It has a characteristic circular structure with a diameter of 14.8 nm and a period of 19.4 nm. The molecule is expressed in various tissues and cells in the human body, including the brain, heart, liver, and pancreas. Its expression level varies depending on the cell type and the developmental stage of the organism.

Function

INO80B-WBP1 has been shown to play a role in various biological processes in the human body. One of its functions is to regulate gene expression by binding to specific DNA sequences. This interaction between INO80B-WBP1 and DNA has been observed in various organisms, including humans. The binding of INO80B-WBP1 to DNA allows it to modulate gene expression, thereby controlling the function of cells and tissues.

Another function of INO80B-WBP1 is to participate in the regulation of cellular processes, including cell adhesion, migration, and the regulation of ion channels. Its expression has been observed in various cell types, including neurons, endothelial cells, and cancer cells. These cells play a crucial role in the development and progression of various diseases, including cancer. Therefore, targeting INO80B-WBP1 as a drug target or biomarker for cancer therapy could be a promising strategy.

Drug Sensitivity

The drug sensitivity of INO80B-WBP1 has been studied in various cell lines and cancer samples. Results have shown that INO80B-WBP1 can be targeted by small molecules, including inhibitors of tyrosine kinase, inhibitors of RNA polymerase, and small molecules that can modulate its expression level. These drugs have been shown to reduce the expression of INO80B-WBP1 in cancer cells, leading to the inhibition of its functions in these cells.

Clinical Applications

The potential clinical applications of INO80B-WBP1 as a drug target or biomarker are vast. Cancer is a leading cause of death worldwide, and there is a high demand for effective treatments. INO80B-WBP1 has been shown to be a promising target for cancer therapy by modulating its functions in cancer cells.

One of the most promising strategies for targeting INO80B-WBP1 is the use of small molecules that can inhibit its expression or activity. These drugs can be administered to cancer patients to reduce the growth of cancer cells and improve their overall quality of life. Currently, there are several INO80B-WBP1-targeted small molecules that are being evaluated in clinical trials.

Another potential application of INO80B-WBP1 is its use as a biomarker for cancer diagnosis and monitoring. The expression of INO80B-WBP1 can be used as a proxy for the presence and progression of cancer. This can be done by using qRT-PCR or western blotting techniques to measure the expression of INO80B-WBP1 in cancer tissue or blood samples. The level of INO80B-WBP1 expression can be used to monitor the effectiveness of cancer treatments and to predict the risk of recurrence.

Conclusion

INO80B-WBP1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns have made it an attractive target for researchers to study and potentially exploit its functions in the human body. Further research is needed to fully understand the role of INO80B-WBP1 in various biological processes

Protein Name: INO80B-WBP1 Readthrough (NMD Candidate)

The "INO80B-WBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INO80B-WBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets